1241914-87-3

Basic information

• Product Name: (4-fluorophenyl)(4-((5-Methyl-1H-pyrazol-3-yl)aMino)quinazolin-2-yl)Methanol
• Synonyms: (4-fluorophenyl)(4-((5-Methyl-1H-pyrazol-3-yl)aMino)quinazolin-2-yl)Methanol
• CAS NO: 1241914-87-3
• Molecular Formula: C₁₉H₁₆FN₅O
• Molecular Weight: 349.3616432
• Mol File: 1241914-87-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 528.8±50.0 °C(Predicted)
• Appearance: /
• Density: 1.421±0.06 g/cm3(Predicted)
• PKA: 12.61±0.20(Predicted)
• CAS DataBase Reference: (4-fluorophenyl)(4-((5-Methyl-1H-pyrazol-3-yl)aMino)quinazolin-2-yl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-fluorophenyl)(4-((5-Methyl-1H-pyrazol-3-yl)aMino)quinazolin-2-yl)Methanol(1241914-87-3)
• EPA Substance Registry System: (4-fluorophenyl)(4-((5-Methyl-1H-pyrazol-3-yl)aMino)quinazolin-2-yl)Methanol(1241914-87-3)

Safety Data

• Hazardous Substances Data: 1241914-87-3(Hazardous Substances Data)

Usage

General Description

The chemical "(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol" is a complex organic compound with a molecular structure containing a fluorophenyl group, an aminoquinazolinyl group, and a methyl-pyrazolylamino group. It is a quinazoline derivative and may have potential pharmaceutical or research applications due to its unique structure. The presence of a fluorine atom in the phenyl group and a methyl group in the pyrazolylamino group may impart specific properties or reactivity to the compound, which could be of interest for further investigation in the fields of medicinal chemistry or drug development.

Upstream product

• 1241914-71-5 (4-fluorophenyl)(4-(5-methyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)methanone 
• 34632-69-4 ethyl 4-chloro-quinazoline-2-carboxylate 
• 1241914-67-9 (4-chloroquinazolin-2-yl)(3-fluorophenyl)methanone 
• 1241914-72-6 (4-chloroquinazoline-2-yl)(4-fluorophenyl)methanone 
• 17318-03-5 bromo(3-fluorophenyl)magnesium 
• 352-13-6 4-flourophenylmagnesium bromide 

Downstream Products

• 1361415-87-3 (R)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol R-(-)-camphorsulfonic acid salt 
• 1361415-86-2 (S)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol hydrochloride 
• 1361415-84-0 (S)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol 
• 1361415-85-1 (R)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol 
• 1359828-49-1 (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol hydrobromide salt 

Relevant articles and documents

THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR AND/OR A CDK 4/6 INHIBITOR

Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ, a Janus kinase-2 (JAK-2) inhibitor, a cyclin-dependent kinase- 4/6 (CDK4/6) inhibitor, and/or a Bruton's tyrosine kinase (BTK) inhibitor are described. In certain embodiments, the invention includes therapeutic combinations of a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor and a BTK inhibitor, a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a JAK-2, PI3K-δ, and BTK inhibitor.

THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR AND/OR A JAK-2 INHIBITOR

Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a ΡΙ3Κ-δ inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, ΡΙ3Κ-δ inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF

Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. (I).